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Stretch of β1 integrins activates an outwardly rectifying, tamoxifen-sensitive Cl− current (Cl− SAC) via AT1 recep-
tors, NADPH oxidase, and reactive oxygen species, and Cl− SAC resembles the volume-sensitive Cl− current 
(ICl,swell). Epidermal growth factor receptor (EGFR) kinase undergoes transactivation upon stretch, integrin en-
gagement, and AT1 receptor activation and, in turn, stimulates NADPH oxidase. Therefore, we tested whether Cl− 
SAC is regulated by EGFR kinase signaling and is volume sensitive. Paramagnetic beads coated with mAb for β1 in-
tegrin were attached to myocytes and pulled with an electromagnet. Stretch activated a Cl− SAC that was 1.13 ± 
0.10 pA/pF at +40 mV. AG1478 (10 μM), an EGFR kinase blocker, inhibited 93 ± 13% of Cl− SAC, and intracellu-
lar pretreatment with 1 μM AG1478 markedly suppressed Cl− SAC activation. EGF (3.3 nM) directly activated an 
outwardly rectifying Cl− current (0.81 ± 0.05 pA/pF at +40 mV) that was fully blocked by 10 μM tamoxifen, an 
ICl,swell blocker. Phosphatidylinositol 3-kinase (PI-3K) is downstream of EGFR kinase. Wortmannin (500 nM) and 
LY294002 (100 μM), blockers of PI-3K, inhibited Cl− SAC by 67 ± 6% and 91 ± 25% respectively, and the EGF-
  induced Cl− current also was fully blocked by LY294002. Furthermore, gp91ds-tat (500 nM), a cell-permeable, chi-
meric peptide that specifi  cally blocks NADPH oxidase assembly, profoundly inhibited the EGF-induced Cl− current. 
Inactive permeant and active impermeant control peptides had no effect. Myocyte shrinkage with hyperosmotic 
bathing media inhibited the Cl− SAC and EGF-induced Cl− current by 88 ± 9% and 127 ± 11%, respectively. 
These results suggest that β1 integrin stretch activates Cl− SAC via EGFR, PI-3K, and NADPH oxidase, and that 
both the Cl− SAC and the EGF-induced Cl− currents are likely to be the volume-sensitive Cl− current, ICl,swell.
Abbreviations used in this paper: AngII, angiotensin II; Cl− SAC, 
stretch-activated Cl− current; DPI, diphenyleneiodonium; EGF, epi-
dermal growth factor; EGFR, EGF receptor; FAK, focal adhesion 
  kinase; HB-EGF, heparin-binding EGF; PI-3K, phosphatidylinositol 
3-kinase; PtdIns(3,4)P2, phosphatidylinositol 3,4 bisphosphate; 
PtdIns(3,4,5)P3, phosphatidylinositol 3,4,5-triphosphate; ROS, reac-
tive oxygen species; RTK, receptor tyrosine kinase.
Correspondence to Clive M. Baumgarten:
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INTRODUCTION
Integrins are transmembrane heterodimeric receptors 
that transmit force from the extracellular matrix to the 
cytoskeleton and activate multiple signaling cascades. 
The  β1D-splice variant is the principal integrin iso-
form expressed in adult mammalian heart (Zhidkova 
et al., 1995). We have shown that specifi  c stretch of β1 
integrin in ventricular myocytes under isosmotic con-
ditions activates an outwardly rectifying Cl− current 
(Cl− SAC) (Browe and Baumgarten, 2003, 2004) that 
resembles the volume-sensitive Cl− current, ICl,swell 
  (Sorota, 1992; Tseng, 1992). Cl− SAC, like ICl,swell, con-
tributes to the background current, activates slowly 
over several minutes, exhibits outward rectifi  cation, 
partially inactivates at positive potentials, and is 
blocked by tamoxifen. Regulation of Cl− SAC involves 
Src and/or focal adhesion kinase (FAK), angiotensin 
AT1 receptors, and reactive oxygen species (ROS) gen-
erated, at least in part, by NADPH oxidase. Further-
more, angiotensin II (AngII) and H2O2 each elicit Cl− 
SAC in ventricular myocytes in the absence of stretch 
(Browe and Baumgarten, 2004).
Stretch (Oeckler et al., 2003), integrins (Moro et al., 
2002), and AT1 receptors (Shah and Catt, 2003) trans-
activate epidermal growth factor receptor (EGFR) 
kinase, a member of the ErbB family of receptor tyro-
sine kinases (RTKs). Unstimulated EGFR kinase is a 
monomer consisting of an extracellular ligand binding 
domain, a single membrane spanning domain, and a 
cytoplasmic kinase domain (Holbro and Hynes, 2004). 
With ligand binding, EGFR kinase dimerizes, trans-
  autophosphorylates six specifi  c tyrosines within its non-
catalytic cytoplasmic tail, and translocates from caveolae 
to costameres (Shah, 2002). EGFR kinase then recruits 
and phosphorylates various adaptor and signaling mol-
ecules that bind phosphotyrosine motifs with their SH2 
and PTB domains and serves as a platform for integrat-
ing downstream signaling.
Signaling by EGFR kinase and AT1 receptors is medi-
ated by phosphatidylinositol 3-kinase (PI-3K), a family 
of lipid kinases also activated by integrins, stretch, and 
H2O2 (Ushio-Fukai et al., 1999; Oudit et al., 2004). The 
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of a p110 catalytic subunit tightly coupled to a regula-
tory subunit. Cardiac myocytes principally   express the 
p110α and γ isoforms that couple with the p85 and p101 
  regulatory   subunits, respectively (Prasad et al., 2003; 
Oudit et al., 2004). The p110α-p85 and p110γ-p101 
  dimers are   activated by interaction with phosphotyro-
sines or the βγ subunit of heterotrimeric G proteins, 
  respectively, and catalyze inositol ring phosphorylation 
at the D-3 position to   produce phosphatidylinositol 
3,4,5-triphosphate (PtdIns(3,4,5)P3) and phosphatidyl-
inositol 3,4-bisphosphate (PtdIns(3,4)P2), potent sig-
naling molecules.
EGFR kinase and PI-3K also participate in the activa-
tion of NADPH oxidase (Seshiah et al., 2002; Vignais, 
2002). Cardiac myocytes express a transmembrane 
  fl  avocytochrome  b558 complex consisting of gp91phox 
(Nox2) and p22phox, as well as the cytosolic components 
p47phox, p67phox, and Rac (Li et al., 2002; Xiao et al., 
2002; Heymes et al., 2003). Nox4, a homologue of 
  gp91phox, also is expressed (Byrne et al., 2003). NADPH 
oxidase activation involves translocation of the cyto-
solic components to the membrane and their assembly 
with fl  avocytochrome b558 (Vignais, 2002). Once assem-
bled, the NADPH oxidase complex uses intracellular 
NADPH as substrate to catalyze the single electron 
  reduction of molecular O2 to superoxide anion, ⋅O2
−, 
which is subsequently converted to H2O2 by superoxide 
dismutase (SOD).
Assembly of the active NADPH oxidase requires the 
binding of gp91phox to p47phox (Vignais, 2002). Recently, 
a cell permeable, chimeric peptide that inhibits this in-
teraction was developed (Rey et al., 2001). The inhibi-
tor, gp91ds-tat, combines the 9-mer gp91phox docking 
sequence for p47phox with a 9-mer from the HIV tat 
  sequence that mediates membrane permeation. gp91
ds-tat can be used to selectively evaluate the role of 
NADPH oxidase in regulating Cl− SAC without affect-
ing ROS production at other sites, such as the fl  avocyto-
chromes within the mitochondria.
The aim of this study was to examine the role of EGFR 
kinase, PI-3K, and NADPH oxidase in the activation of 
Cl− SAC in ventricular myocytes and to determine 
whether Cl− SAC is volume sensitive. Paramagnetic 
beads coated with anti–β1 integrin mAb were used to 
stretch integrins. Block of EGFR kinase or PI-3K during 
stretch inhibited Cl− SAC. Moreover, exogenous epider-
mal growth factor (EGF) fully activated Cl− SAC, and 
the EGF-induced current was inhibited by PI-3K and 
NADPH oxidase blockers and by tamoxifen, a blocker 
of ICl,swell. Finally, Cl− SAC elicited by either integrin 
stretch or exogenous EGF was volume sensitive and 
was completely inhibited by osmotic shrinkage. Thus, 
the Cl− SAC and EGF-induced Cl− current are likely to 
be carried by the same channel as ICl,swell. A preliminary 
  report appeared previously (Browe and Baumgarten, 
2005b).
MATERIALS AND METHODS
Ventricular Myocyte Isolation
Left ventricular myocytes were freshly isolated from adult New 
Zealand white rabbits ( 3 kg) of either gender. Hearts were ex-
cised, attached to a Langendorff perfusion apparatus, and sub-
jected to an enzymatic dissociation procedure described previously 
(Browe and Baumgarten, 2003). Isolated myocytes were washed 
and stored in a modifi  ed KB medium. All experimental record-
ings were conducted within 10 h of myocyte isolation. Single myo-
cytes chosen for study were rod-shaped, quiescent, displayed clear 
striations, and were free of membrane blebs or other morphologi-
cal irregularities.
Tyrode solution for cell isolation contained (in mM) 130 NaCl, 
5 KCl, 1.8 CaCl2, 0.4 KH2PO4, 3 MgCl2, 5 HEPES, 15 taurine, 
5 creatine, 10 glucose, pH 7.25 (adjusted with NaOH). CaCl2 was 
replaced with 0.1 mM Na2-EGTA to make Ca2+-free Tyrode solu-
tion. Enzyme solution contained 1.5–1.75 mg/ml BSA (Sigma-
  Aldrich; A7906), 0.5 mg/ml collagenase (type II, Worthington), 
and 0.05 mg/ml pronase (Sigma-Aldrich; type XIV) in nominally 
Ca2+-Tyrode solution without EGTA. All isolation solutions were 
well oxygenated and maintained at 37°C. Modifi  ed KB medium 
contained (in mM) 120 K-glutamate, 10 KCl, 10 KH2PO4, 0.5 K2-
EGTA, 10 taurine, 1.8 MgSO4, 10 HEPES, 20 glucose, 10 manni-
tol, pH 7.2 (adjusted with KOH).
Experimental Solutions and Drugs
Single ventricular myocytes were scattered on a poly-l-lysine–
coated, glass-bottomed chamber and placed on the stage of 
an inverted microscope (Diaphot; Nikon). Hoffman modula-
tion   optics (×40; NA = 0.55) and a high resolution TV camera 
(CCD72; Dage-MTI) were used to visualize the cells. Bath solution 
designed to isolate anion currents was suprafused at 2–3 ml/min 
and contained (in mM) 145 N-methyl-d-glucamine (NMDG)-Cl, 
4.3 MgCl2, 10 HEPES, 5 glucose, pH 7.4 (adjusted with NMDG). 
Pipette solution contained (in mM) 110 Cs-  aspartate, 20 CsCl, 
2.5 Mg-ATP, 8 Cs2-EGTA, 0.1 CaCl2, 10 HEPES, pH 7.1 (adjusted 
with CsOH; liquid junction potential, −13.2 mV). Pipette free-
Ca2+ was estimated to be  35 nM (WinMAXC 2.4; www.stanford.
edu/~cpatton/maxc.html). All recordings were made at room 
temperature (22°C–23°C).
The tyrphostin AG1478 (1 mM; Calbiochem), tamoxifen 
(20 mM; Sigma-Aldrich), wortmannin (1 mM, Calbiochem), 
and LY294002 (50 mM, Calbiochem) were prepared as stock 
solutions in DMSO at the indicated concentrations and kept 
frozen (−20°C) in small aliquots until use. EGF (mouse; Cal-
biochem) was dissolved directly in bath solution and kept fro-
zen (−20°C) in small aliquots until use at a fi  nal concentration 
of 3.3 nM, which is equivalent to 20 ng/ml. A membrane-
  permeant inhibitor of NADPH oxidase, gp91ds-tat, an inactive 
membrane-permeant analogue, scramb-tat, and an active but 
impermeant gp91ds peptide were synthesized by the Tufts Uni-
versity Core Facility, as   previously described by others (Rey 
et al., 2001). The inhibitor, gp91ds-tat, is a fusion peptide made 
from a 9-mer, CSTRIRRQL, that inhibits assembly of NADPH 
oxidase by mimicking the gp91phox docking site for the cytoplas-
mic p47phox subunit and a 9-mer from the tat HIV coat protein 
that confers membrane permeability. The   gp91phox docking site 
sequence is identical in a number of   experimental species in-
cluding rabbit (Gauss et al., 2002), but   experimental evidence 
and homology suggest that gp91ds-tat may not distinguish 
  between gp91phox homologues (Rey et al., 2001). The inactive 
  fusion peptide, scramb-tat, was made by scrambling the 9-mer 
docking peptide to minimize matches in the GenBank/EMBL/
DDBJ database, whereas gp91ds is the docking site 9-mer 
  without tat and is active in broken cell systems. Each peptide 
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  acidifi  ed with 10 mM acetic acid and kept frozen (−20°C) in 
small   aliquots until use. For certain experiments, bath solution 
osmolarity was increased from 300 mosmol/kg (1T) to 450 
mosmol/kg (1.5T) by addition of mannitol, preserving a con-
stant ionic strength.
Integrin Stretch
Force was applied directly and specifi  cally to β1 integrins using 
mAb-coated paramagnetic beads and an electromagnet, as pre-
viously described (Browe and Baumgarten, 2003). mAb for the 
β1 subunit of integrin (MAB2250, IgG1; Chemicon) was attached 
by anti–pan IgG mAb to the surface of uniform 4.5 ± 0.2 μm 
diameter (mean ± SD) superparamagnetic beads containing 
iron oxides (dynabeads M-450 pan mouse IgG; Dynal Biotech). 
Anti-β1 integrin mAb–coated beads were added to myocytes in 
the bath and were permitted to randomly settle on myocytes 
from above while the fl  ow of bath solution was turned off. Af-
ter  5 min,   unbound beads were washed away by restoring fl  ow. 
Myocytes chosen for study typically had three to fi  ve coated beads 
on their surface, and presumably, each bead was bound to mul-
tiple β1 integrins.
A water-cooled electromagnet was placed directly on top of 
the bath, and patch pipettes were passed through an opening at 
the base of the coil. Current through the coil was set to generate 
a magnetic fl  ux density of 35 Gauss (G) and a magnetic fl  ux den-
sity gradient of 2,400 G/m that was uniform in the x–y plane 
  occupied by the myocytes on the chamber fl  oor. The resulting 
force vector imposed on each bead was directed upwards toward 
the coil, perpendicular to the long axis of the myocyte, and was 
estimated to have a magnitude of 1.2 pN/bead (Browe and 
Baumgarten, 2003).
Electrophysiological Recordings
Pipettes were pulled from 7740 thin-walled borosilicate glass 
capillary tubing (Sutter) and fi  re polished to give a fi  nal tip 
  diameter of 3–4 μm and resistance in bath solution of 2–3 MΩ. 
Membrane currents were recorded with an EPC-7 amplifi  er 
(List-Medical) using the whole cell confi  guration. A 150 mM 
KCl agar bridge served as the ground electrode. Seal resistances 
of 5–30 GΩ were typically obtained. Membrane potential was 
corrected for the measured liquid junction potential before 
forming a seal. After seal formation, the membrane patch was 
ruptured by application of negative pressure or by a brief 
  zapping pulse. Myocytes were dialyzed for at least 10 min before 
recordings commenced. Voltage clamp protocols and data 
  acquisition were governed by a Digidata 1200B or 1322A and 
pClamp 8.0 (Axon Instruments). Successive 500-ms voltage steps 
were taken from a holding potential of −60 mV to test potentials 
ranging from −100 to +40 mV in +10 mV increments.  Membrane 
currents were low-pass fi   ltered at 2 kHz (8-pole Bessel 902, 
  Frequency Devices) and digitized at 10 kHz. For presentation, 
  selected records were low-pass fi  ltered at 50 Hz post-digitization 
with a Gaussian fi  lter in PClamp. Cl− currents exhibited strong 
voltage-dependent inactivation, and isochronal IV curves were 
plotted based on the average current recorded 20–35 ms after the 
onset of the voltage step.
Statistics
Data are reported as mean ± SEM; n denotes the number of cells. 
Mean currents are expressed as current density (pA/pF) to ac-
count for differences in myocyte surface membrane area, and 
paired comparisons usually are expressed as a percentage. Statis-
tical analyses were performed by SigmaStat 3.1 (Systat). For mul-
tiple comparisons, a one-way repeated measures ANOVA was 
performed and was followed by a Student-Newman-Keuls test. For 
comparisons of two groups, a one-tailed paired Students t test was 
conducted. In both cases, P < 0.05 was taken as signifi  cant.
RESULTS
EGFR Kinase Participates in Cl− SAC Activation
Integrins, AT1 receptors, and mechanical stretch initi-
ate transactivation of EGFR kinase (Moro et al., 2002; 
Oeckler et al., 2003; Shah and Catt, 2003). Because 
EGFR kinase serves as a nexus for integrating diverse 
stimuli that regulate Cl− SAC, we assessed its role in the 
response to β1 integrin stretch. Fig. 1 illustrates families 
of anion currents at test potentials between −100 and 
+40 mV and the corresponding I–V relationships. Un-
der control conditions with anti-β1 integrin mAb–coated 
paramagnetic beads attached to the myocyte surface 
but before the application of integrin stretch, a small 
outwardly rectifying background current that partially 
inactivated at positive potentials was present (Fig. 1 A). 
The background current reversed at −49 mV, which is 
near the calculated value of −52 mV for ECl (Fig. 1 D). 
Partial activation of ICl,swell is thought to occur under 
these conditions, and the background Cl− current is 
sensitive to the ICl,swell blocker tamoxifen (Hume et al., 
2000). Consequently, ICl,swell is likely to comprise much 
of the background Cl− current observed in 1T. Stretch 
Figure 1.  AG1478, a specifi  c EGFR kinase blocker, inhibits Cl− 
SAC but does not affect background current in the absence of 
stretch. Families of currents recorded before (A, Control) and after 
(B, Stretch) activation of Cl− SAC by β1 integrin stretch (5 min), 
and after addition of AG1478 (10 μM, 10 min) to the bath with 
continued stretch (C, +AG1478). Holding potential, −60 mV; 
test potentials, −100 to +40 mV; step duration, 500 ms. Horizontal 
bar denotes 0 current. (D) I-V relationships for A–C; each reversed 
near −50 mV (ECl = −52 mV). (E) I-V relationships com    paring 
AG1478-sensitive current after stretch (Stretch-AG1478) and the 
AG1478-sensitive background current (Control-AG1478) in the 
  absence of stretch in different myocytes. At +40 mV, stretch-
  induced Cl− current was 1.13 ± 0.10 pA/pF, and AG1478 reduced 
Cl− SAC by 93 ± 13% (n = 4, P = 0.001) but did not affect back-
ground current (n = 4; P = 0.526) in   unstretched myocytes.240 Signaling Cascade Regulating Cl− SAC
of β1 integrins progressively increased the magnitude 
of the outward Cl− current over 5 min, giving a more 
than twofold augmentation of outward current at +40 
mV in this example (Fig. 1, B and D). After full  activation 
by stretch, the Cl− current partially inactivated at  positive 
potentials, and its I–V relationship showed strong out-
ward rectifi  cation and reversed near ECl, as previously 
shown (Browe and Baumgarten, 2003, 2004).
Block of EGFR kinase with 10 μM AG1478, a selective 
inhibitor (Levitzki and Gazit, 1995), almost completely 
abrogated the stretch-induced Cl− current in the con-
tinued presence of integrin stretch (Fig. 1, C and E). 
The I–V relationship was nearly restored to its control 
level after 10 min, and the reversal potential was unaf-
fected. Overall, integrin stretch increased the Cl− cur-
rent at +40 mV from 1.33 ± 0.07 to 2.30 ± 0.22 pA/pF, 
and exposure to AG1478 (10–12 min) with continued 
integrin stretch reduced the current to 1.46 ± 0.17 pA/
pF (n = 4). Thus, block of EGFR kinase inhibited 93 ± 
13% (n = 4, P = 0.001) of stretch-induced current at 
+40 mV, and the current after block was not signifi  -
cantly different from the control current (n = 4, P = 
0.385). Neither stretch of β1 integrin nor subsequent 
AG1478 application signifi  cantly altered inward current 
at  −100 mV, however, as also was shown for stretch 
(Browe and Baumgarten, 2003, 2004).
As a control, we examined the effect of AG1478 (10 μM, 
10 min) on the background Cl− current in the absence 
of integrin stretch. In contrast to its pronounced inhibi-
tory effect on the stretch-induced outward current, 
AG1478 did not signifi  cantly alter the background Cl− 
current (Fig. 1 E) at either +40 mV (n = 4; P = 0.526) 
or −100 mV (n = 4; P = 0.306).
AG1478 also prevented activation of Cl− SAC when it 
was applied intracellularly before integrin stretch. Myo-
cytes were pretreated by including 1 μM AG1478, a 10-
fold lower concentration, in the pipette solution. After 
15–20 min of dialysis, myocytes were stretched for 
10 min, a time suffi  cient to fully activate Cl− SAC (Browe 
and Baumgarten, 2003). After pretreatment, stretch 
elicited a small but statistically insignifi  cant  current, 
0.23 ± 0.14 pA/pF, at +40 mV (n = 5, P = 0.10). This 
current was only 23% of that observed without pretreat-
ment, 0.97 ± 0.09 pA/pF (n = 18).
Exogenous EGF Activates Cl− SAC
If transactivation of EGFR kinase is an upstream signal-
ing event in the activation of Cl− SAC, exogenous EGF, 
which binds EGFR kinase and stimulates FAK and Src 
activity and ROS production (Brunton et al., 1997; Park 
et al., 2004), might be expected to mimic the effect of 
integrin stretch. Fig. 2 illustrates the effect of exoge-
nous EGF on Cl− currents in the absence of integrin 
stretch. Under control conditions, a typical background 
current was observed (Fig. 2, A and E). Addition of 3.3 nM 
EGF to bathing solution for 6 min evoked an outwardly 
  rectifying Cl− current that exhibited partial inactivation 
at positive potentials (Fig. 2, B and E). The EGF-induced 
difference current (Fig. 2, D and F) was obtained by   
digital subtraction. Overall, exogenous EGF (5–6 min) 
  increased the outward Cl− current at +40 mV by 0.81 ± 
0.05 pA/pF (n = 24, P < 0.001), from 1.20 ± 0.07 to 2.01 
±0.08 pA/pF. As found with stretch, EGF had a very 
modest effect on the inward Cl− current. At −100 mV, 
EGF increased inward current by 0.04 ± 0.01 pA/pF 
(n = 24; P < 0.001), from −0.24 ± 0.02 to −0.28 ± 0.03 
pA/pF. Signifi  cant effects of EGF on inward current were 
not consistently detected in smaller groups, however.
To further characterize the EGF-induced current, we 
examined its sensitivity to tamoxifen. Tamoxifen  inhibits 
Cl− SAC and ICl,swell but does not affect either the PKA-
regulated CFTR or the Ca2+-activated Cl− currents 
(Hume et al., 2000; Browe and Baumgarten, 2003). 
  After full activation of Cl− current by 3.3 nM EGF, 
Figure 2.  Exogenous EGF activates Cl− current in the absence of 
integrin stretch. Currents before (A, Control) and after (B, EGF) 
exposure to EGF (3.3 nM, 6 min), and after addition of the Cl− SAC 
and ICl,swell blocker tamoxifen (10 μM, 6 min) in the continued pres-
ence of EGF (C, +Tamoxifen). EGF-induced difference current (D, 
EGF-Induced) was obtained by digital subtraction. I-V relationships 
for A-C (E) and for the EGF-induced current (F). Each I-V relation-
ship reversed near ECl. The EGF-induced Cl− current partially inac-
tivated at positive potentials, exhibited strong outward rectifi  cation, 
and both the EGF-induced and background Cl− currents were com-
pletely blocked by tamoxifen. At +40 mV, the Cl− current elicited 
by EGF was 0.81 ± 0.05 pA/pF (n = 24, P < 0.001), and tamoxifen 
reduced the current by 170 ± 8% (n = 4, P < 0.001).Browe and Baumgarten 241
  exposure to 10 μM tamoxifen for 6 min in the contin-
ued presence of EGF completely abolished the EGF-
  induced Cl− current as well as a large fraction of the 
background Cl− current (Fig. 2, C and E). In these ex-
periments,   tamoxifen (6–8 min) blocked 170 ± 8% 
(n = 4; P < 0.001) and 177 ± 55% (n = 4; P < 0.02) of 
the EGF-induced current at +40 and −100 mV, respec-
tively. EGF increased the Cl− current at +40 mV from 
1.15 ± 0.09 to 1.85 ± 0.06 pA/pF (n = 4; P < 0.001), and 
tamoxifen reduced the current to 0.67 ± 0.13 pA/pF, a 
value signifi  cantly less than control (n = 4; P < 0.01).
Fig. 3 compares the time course of Cl− currents at 
+40 mV after activation by either EGF (3.3 nM) or integ-
rin stretch, and as a control for time, the background 
current in the absence of an intervention. The EGF-
  induced Cl− current was well described by a single ex-
ponential with a time constant of 3.2 ± 0.9 min (n = 4), 
equivalent to a t1/2 of 2.2 ± 0.6 min, and was 0.91 ± 0.07 
pA/pF at 20 min. Activation by integrin stretch was 
slower and sigmoidal with a t1/2 of 4.3 ± 0.6 min (n = 4), 
and the steady-state current was 1.19 ± 0.07 pA/pF. 
Once activated, both currents remained at stable levels 
for the remainder of the recording period. In the ab-
sence of an intervention, the background current was 
stable for 20 min. The more rapid activation of Cl− cur-
rent by EGF as compared with stretch is consistent with, 
but does not prove, the idea that EGF is a downstream 
event in the stretch-induced signaling cascade regulat-
ing Cl− SAC. Moreover, these data demonstrate the sta-
bility of the current recordings and serve as a time 
control for studies with blockers.
Role of PI-3K
Mechanical stretch, cell swelling, and integrin clustering 
all activate PI-3K (Sadoshima and Izumo, 1997; Franchini 
et al., 2000). Upon integrin clustering, activation of FAK 
and Src leads to the recruitment of PI-3K to costameres 
(Franchini et al., 2000), and PI-3K regulates NADPH ox-
idase activity (Vignais, 2002). Fig. 4 illustrates a test of 
the idea that PI-3K also participates in the activation of 
Cl− SAC in response to β1 integrin stretch using wort-
mannin, an irreversible blocker of PI-3K (Stein and 
  Waterfi  eld, 2000). After activating Cl− SAC by β1  integrin 
stretch for 6 min (Fig. 4, B and D), exposure to 500 nM 
wortmannin for 12 min with continued integrin stretch 
partially inhibited the outward Cl− SAC (Fig. 4, C and D). 
Wortmannin (12–15 min) blocked 67 ± 6% (n = 7; P < 
0.001) of the Cl− SAC at +40 mV. Stretch increased the 
Cl− current from 1.45 ± 0.14 to 2.47 ± 0.17 pA/pF, and 
wortmannin reduced the current to 1.81 ± 0.12 pA/pF 
(n = 7; P < 0.001). Although block of Cl− SAC by wort-
mannin at +40 mV was substantial, the current remained 
signifi  cantly greater than control (n = 7; P = 0.006). 
Surprisingly, wortmannin (500 nM, 12 min) augmented 
the outward background current in the absence of 
stretch (Fig. 4 E). At +40 mV, the Cl− current was in-
creased by 15 ± 5% (n = 4; P = 0.02), from 1.16 ± 0.14 
to 1.33 ± 0.16 pA/pF. The basis for the stimulation of 
background Cl− current was not investigated further.
Figure 3.  Time courses of Cl− currents activated by EGF (3.3 nM) 
and integrin stretch and the background current. Currents at 
+40 mV were recorded at 1-min intervals for 20 min. Stretch- and 
EGF-induced currents were normalized by their steady-state 
  values, 1.19 ± 0.07 (n = 4) and 0.91 ± 0.07 (n = 4), respectively, 
and the background current was normalized by the steady-state 
current after stretch. Cl− current activation by EGF exhibited an 
exponential time course (τ = 3.2 ± 0.9 min; n = 4; equivalent 
t1/2 = 2.2 ± 0.6 min), while activation by integrin stretch followed 
a slower, sigmoidal time course (t1/2 = 4.3 ± 0.6 min; n = 4). The 
background current was nearly constant throughout the  recording 
period in unstimulated myocytes. Solid lines are fi  ts to averaged 
data; dashed line is zero current.
Figure 4.  Wortmannin, a PI-3K blocker, partially inhibited Cl− 
SAC. Currents before (A, Control) and after (B, Stretch) integrin 
stretch (6 min), and after exposure to wortmannin (500 nM, 
12 min) with continued stretch (C, +Wort). (D) I-V relationships 
for A–C; each reversed near ECl. (E) I-V relationships comparing 
the wortmannin-sensitive current after integrin stretch (Stretch-
Wort) and the wortmannin-sensitive background current (Wort-
  Control) in different myocytes. At +40 mV, wortmannin inhibited 
67 ± 6% (n = 7; P < 0.001) of the Cl− SAC. In contrast, wortman-
nin   elicited a small increase in background current at +40 mV, 
15 ± 5% (n = 4; P = 0.02), in unstretched myocytes.242 Signaling Cascade Regulating Cl− SAC
To verify the involvement of PI-3K in the response to 
  integrin stretch, LY294002 was employed. LY294002 is 
  structurally and mechanistically distinct from wortmannin 
and  reversibly inhibits PI-3K (Stein and Waterfi  eld, 
2000; Oudit et al., 2004). Fig. 5 confi  rms the sensitivity 
of Cl− SAC to block of PI-3K. After activating Cl− SAC by 
β1 integrin stretch for 5 min, exposure to LY294002 
(20 μM, 15 min) with continued stretch blocked al-
most all of the Cl− SAC (Fig. 5, A and B). Stretch in-
creased the current at +40 mV from 1.14 ± 0.28 to 
1.86 ± 0.36 pA/pF (n = 4; P < 0.001), and LY294002 
(20 μM, 15 min) reduced the current by 99 ± 11% (n = 4; 
P < 0.001). The current remaining in the presence of 
LY294002, 1.20 ± 0.35 pA/pF, was not signifi  cantly dif-
ferent from the control current (n = 4; P = 0.54). In 
contrast to its pronounced inhibition of the stretch-
  induced current, LY294002 (20 μM, 15 min) had a negli-
gible effect on the background current in the absence 
of stretch (Fig. 5 C). At +40 mV, LY294002 reduced 
background current by only 3 ± 1% (n = 4; P = 0.07), 
from 0.62 ± 0.07 to 0.60 ± 0.08 pA/pF.
EGFR kinase also utilizes PI-3K as one of its principal 
downstream mediators of signaling (Bogdan and 
Klämbt, 2001). Therefore, we tested whether the Cl− 
current elicited by exogenous EGF (3.3 nM, 6 min) also 
depended on PI-3K. LY294002 (20 μM, 12 min) inhib-
ited almost all of the EGF-induced current in the con-
tinued presence of EGF. Overall, EGF increased the Cl− 
current at +40 mV from 0.97 ± 0.10 to 1.66 ± 0.09 pA/
pF, and LY294002 (20 μM, 12–14 min) blocked 124 ± 
16% (n = 4; P < 0.001) of the current elicited by EGF. 
The current remaining after LY294002, 0.82 ± 0.14 
pA/pF, was not significantly different from the con-
trol (n = 4; P = 0.15). The inward currents at −100 mV 
were small and were not signifi  cantly affected in this set 
of experiments. Thus, block of PI-3K by LY294002 had 
the same inhibitory effect on the EGF- and integrin 
stretch–induced Cl− currents but no effect on the out-
wardly rectifying background current.
Role of NADPH Oxidase in EGF-induced Cl− Current
Previously we provided evidence that activation of Cl− 
SAC by integrin stretch involves NADPH oxidase and 
the production of ROS (Browe and Baumgarten, 2004). 
EGFR kinase and PI-3K are known to participate in the 
activation of NADPH oxidase (Seshiah et al., 2002). 
As illustrated in Fig. 6, we tested whether the Cl− cur-
rent evoked by exogenous EGF also requires NADPH 
oxidase activity. First, Cl− current was elicited with EGF 
(3.3 nM, 5 min; Fig. 6, B and D), and then gp91ds-tat, a 
selective membrane-permeant fusion peptide blocker 
of NADPH oxidase (Rey et al., 2001), was added. In the 
continued presence of EGF, gp91ds-tat (500 nM, 
15 min) completely inhibited the EGF-induced Cl− cur-
rent (Fig. 6, C and D). EGF (3.3 nM, 5 min) increased 
outward Cl− current at +40 mV from 1.16 ± 0.15 to 
2.16 ± 0.16 pA/pF (n = 4; P < 0.001), and gp91ds-tat 
(500 nM, 12 – 15 min) inhibited 133 ± 20% (n = 4; 
P <0.001) of the EGF-induced Cl− current. The current 
after gp91ds-tat treatment, 0.94 ± 0.07 pA/pF, was not 
signifi  cantly different from the control current (n = 4; 
P = 0.19). EGF also signifi  cantly increased the inward 
Cl− current at −100 mV from −0.16 ± 0.02 to −0.23 ± 
0.01 pA/pF (n = 4; P < 0.01), and gp91ds-tat reduced 
the current to −0.18 ± 0.01 pA/pF, blocking 87 ± 27% 
(n = 4; P = 0.01).
To rule out nonspecifi  c effects of gp91ds-tat, experi-
ments were conducted with two peptides as negative 
controls. We used scramb-tat, a membrane-permeant 
chimeric peptide that does not interfere with the bind-
ing of gp91phox to p47phox, and gp91ds, which blocks 
NADPH oxidase in broken cell systems but is imper-
meant (Rey et al., 2001). As shown in Fig. 7, Cl− current 
was elicited with EGF (3.3 nM, 5 min). Then, either 
scramb-tat (500 nM, 15 min; Fig. 7 A) or gp91ds 
Figure 5.  LY294002, a PI-3K blocker, completely inhibited 
stretch- and EGF-induced Cl− current but did not affect back-
ground current. (A) I-V relationships before (Control) and after 
(Stretch) activation of Cl− SAC by integrin stretch (5 min), and 
after exposure to LY294002 (20 μM, 15 min) with continued 
stretch (+LY). At +40 mV, LY294002 inhibited 99 ± 11% (n = 4, 
P < 0.001) of the stretch-induced Cl− SAC. (B) I-V relationships 
comparing the LY294002-sensitive current (Stretch-LY) after 
stretch (5 min), and the LY294002-sensitive background current 
(Control-LY) in unstretched myocytes. (C) I-V relationships be-
fore (Control) and after (EGF) activation of Cl− current with EGF 
(3.3 nM, 5 min), and after exposure to LY294002 (20 μM, 
15 min) in the continued presence of EGF (+LY). At +40 mV, 
LY294002 inhibited 124 ± 16% (n  = 4, P < 0.001) of the 
EGF-  induced Cl− current. (D) I-V relationships comparing the 
LY294002-sensitive current after EGF exposure (EGF-LY), and 
the LY294002-sensitive background current (Control-LY; from 
B). LY294002 did not signifi  cantly affect background current 
(n = 4; P = 0.07) in the absence of a stimulus.Browe and Baumgarten 243
(500 nM, 15 min; Fig. 7 B) was applied in the continued 
  presence of EGF. Neither negative control peptide 
  suppressed the EGF-induced current. If anything, the 
currents elicited by EGF continued to increase slightly 
over most of the voltage range positive to −20 mV. In 
the experiments with scramb-tat, EGF increased Cl− 
current at +40 mV from 1.09 ± 0.22 to 2.03 ± 0.18 pA/
pF (n = 4; P < 0.001), and it was 2.04 ± 0.21 pA/pF 
  after a 12–15 min exposure to scramb-tat (n = 4; P = 
0.94). Thus, the tat sequence was not sufficient to 
reproduce the effect of gp91ds-tat. Similarly, in 
experiments with impermeant gp91ds, EGF increased 
the Cl− current at +40 mV from 0.98 ± 0.07 to 1.65 ± 
0.04 pA/pF (n = 3; P = 0.001), and it was 1.61 ± 0.02 
pA/pF after a 12–15 min exposure to impermeant 
gp91ds (n = 3; P = 0.57). The ineffectiveness of active 
but impermeant gp91ds indicates that the site blocked 
by gp91ds-tat must be in the cytoplasm or on the inter-
nal face of the sarcolemma and that gp91ds cannot 
block the EGF-activated Cl− channel from the outside.
Cl− SAC Is a Volume-sensitive Current
Based on its biophysical and pharmacological charac-
teristics, it was hypothesized that the same channel in 
ventricular myocytes is responsible for both the Cl− 
SAC evoked by β1 integrin stretch and the volume-
  sensitive Cl− current, ICl,swell (Browe and Baumgarten, 
2003, 2004). Moreover, both Cl− SAC and ICl,swell are 
regulated by several of the same signaling molecules 
(Browe and Baumgarten, 2003, 2004; Ren and Baumgar-
ten, 2005). If this idea is correct, current elicited by β1 
integrin stretch should be volume sensitive. A test of 
this   prediction is illustrated in Fig. 8. After recording 
control currents in isosmotic 1T bath solution (Fig. 8, 
A and E), Cl− SAC was activated by a 5-min integrin 
stretch in 1T bath solution (Fig. 8, B and E). Suprafu-
sion of 1.5T hyperosmotic bath solution for 10 min 
while integrin stretch was continued completely inhib-
ited the stretch-induced Cl− current (Fig. 8, C and E). 
Moreover, block of the Cl− SAC by osmotic shrinkage 
was reversed by returning to 1T bath solution for 5 min 
while maintaining stretch (Fig. 8, D and E). Inhibition 
of the Cl− SAC by osmotic shrinkage was observed in all 
myocytes studied. Stretch in 1T bath solution increased 
Cl− current at +40 mV from 1.10 ± 0.30 to 2.32 ± 0.57 
pA/pF (n = 4; P = 0.001), and osmotic shrinkage in 
1.5T bath solution (10–12 min) blocked 94 ± 6% (n = 4; 
P < 0.001) of stretch-activated current, reducing the 
current at +40 mV to 1.13 ± 0.24 pA/pF, a value not 
different from control (n = 4; P = 0.91). After reintro-
duction of 1T bathing solution for 5 min, the current 
returned to 2.33 ± 0.51 pA/pF, a value not signifi  cantly 
different from that after the initial period of stretch in 
1T bathing solution (n = 4; P = 0.95).
The effectiveness of 1.5T in blocking the Cl− SAC may 
be overestimated in these experiments because hyper-
osmotic bath solution also blocks a tamoxifen-sensitive, 
outwardly rectifying background Cl− current attributed 
to partial activation of ICl,swell under isosmotic conditions 
(Hume et al., 2000). To estimate the contribution of 
background ICl,swell to the current blocked by 1.5T dur-
ing integrin stretch, unstretched myocytes in 1T were 
Figure 6.  gp91ds-tat, a cell-permeable, chimeric peptide that 
  selectively blocks NADPH oxidase assembly by mimicking the 
  gp91phox docking sequence for p47phox, inhibits EGF-induced Cl− 
current. Currents before (A, Control) and after (B, EGF) activa-
tion of Cl− current by EGF (3.3 nM, 5 min), and after exposure to 
gp91ds-tat (500 nM, 5 min) in the continued presence of EGF 
(C, +gp91ds-tat). (D) I-V relationships for A–C; each reversed 
near ECl. At +40 mV, gp91ds-tat inhibited 133 ± 20% (n = 4, P < 
0.001) of the EGF-induced Cl− current.
Figure 7.  Negative control peptides did not signifi  cantly affect 
EGF-induced Cl− current. Membrane permeant scramb-tat is a 
scrambled docking sequence 9-mer fused to the tat 9-mer, and 
membrane-impermeant gp91ds is the active inhibitory docking 
sequence 9-mer without tat. (A) I-V relationships before (Con-
trol) and after (EGF) exposure to EGF (3.3 nM, 5 min), and after 
addition of scramb-tat (500 nM, 15 min) in the continued pres-
ence of EGF (+scramb-tat). (B) I-V relationships in a separate 
  experiment before (Control) and after (EGF) exposure to EGF 
(3.3 nM, 5 min), and after addition of gp91ds (500 nM, 15 min) 
in the continued presence of EGF (+ gp91ds). At +40 mV, scramb-
tat and gp91ds inhibited the EGF-induced Cl− current by −2 ± 
7% (n = 4, P = ns) and 7 ± 9% (n = 4, P = ns), respectively.244 Signaling Cascade Regulating Cl− SAC
exposed to 1.5T for 10 min. At +40 mV, osmotic shrink-
age in1.5T reduced the background current by 0.53 ± 
0.09 pA/pF (n = 4; P = 0.005), from 1.69 ± 0.37 to 
1.15 ± 0.29 pA/pF (Fig. 8 F). The current remaining 
after shrinkage was the same in the absence, 1.15 ± 0.29 
pA/pF, and presence, 1.13 ± 0.24 pA/pF, of integrin 
stretch. On the other hand, the initial background cur-
rent in the set of cells that were stretched, 1.10 ± 0.30 
pA/pF, was smaller than that in the set that was not 
stretched, 1.69 ± 0.37 pA/pF.
If the EGF-induced Cl− current is the same as the Cl− 
SAC and ICl,swell, it also should be volume sensitive, as is 
demonstrated in Fig. 9. The Cl− current in 1T bathing 
solution (Fig. 9, A and E) was increased by addition of 
EGF (3.3 nM, 5 min; Fig. 9, B and E). The EGF-induced 
current was blocked after 10 min of myocyte shrinkage 
by hyperosmotic 1.5T solution containing EGF (Fig. 9, 
C and E), and block was completely reversed after 
  returning to 1T bath solution containing EGF for 5 min 
(Fig. 9, D and E). Fig. 9 F compares the current blocked 
by 1.5T bathing solution before and after exposure to 
EGF. At +40 mV, EGF in 1T bathing solution increased 
the Cl− current from 1.65 ± 0.19 to 2.32 ± 0.32 pA/pF 
(n = 4; P = 0.003), and exposure to 1.5T bathing solu-
tion with EGF blocked 127 ± 11% (n = 4; P = 0.001) of 
the EGF-induced current. The current after myocyte 
shrinkage, 1.46 ± 0.14 pA/pF, was not signifi  cantly dif-
ferent than the control current (n = 4; P = 0.22). On 
returning to 1T bathing solution with EGF, 94 ± 6% 
(n = 4; P = 0.001) of the initial EGF-induced current 
recovered; the current recorded under these  conditions, 
2.25 ± 0.28 pA/pF, was not signifi  cantly different from 
the initial current with EGF (n = 4; P = 0.64).
DISCUSSION
We previously showed that β1 integrin stretch activates 
an outwardly rectifying, tamoxifen-sensitive Cl− SAC 
Figure 8.  Cl− SAC and the background current both are volume 
sensitive and are inhibited by shrinkage in hyperosmotic 1.5T 
bath solution. Currents before (A; Control, 1T) and after (B; 
Stretch, 1T) Cl− SAC activation by integrin stretch (5 min) in 1T 
bathing solution, after exposure to 1.5T bathing solution (10 
min) in the continued presence of stretch (C; Stretch, 1.5T), and 
after return to 1T bathing solution (5 min) while maintaining 
stretch (D; Stretch, 1T Wash). (E) I-V relationships for A–D. (F) 
I-V relationships comparing the osmotic shrinkage-sensitive com-
ponent of the current after stretch (Stretch-1.5T) and background 
current (Control-1.5T) in different myocytes. At +40 mV, osmotic 
shrinkage inhibited 94 ± 6% (n = 4, P < 0.001) of the stretch-
  induced Cl− SAC, and the inhibition was reversed upon return to 
1T bathing solution (n = 4, P = ns vs. initial 1T, stretch). Further-
more, osmotic shrinkage inhibited 34 ± 4% (n = 4; P = 0.005) of 
the background current in the absence of stretch.
Figure 9.  EGF-induced Cl− current is volume sensitive and is in-
hibited by shrinkage in hyperosmotic 1.5T bathing solution. Cur-
rents before (A; Control, 1T) and after (B; EGF, 1T) activation by 
EGF (3.3 nM, 5 min) in 1T bathing solution, after exposure to 
1.5T bathing solution (10 min) in the continued presence of EGF 
(C; EGF, 1.5T), and after return to 1T bathing solution (5 min) in 
the continued presence of EGF (D; EGF, 1T Wash). (E) I-V rela-
tionships for A–D. (F) I-V relationships comparing the osmotic 
shrinkage-sensitive component of the current after EGF (EGF-
1.5T) and the background current (Control-1.5T; from Fig. 8 F). 
At +40 mV, osmotic shrinkage inhibited 127 ± 11% (n = 4, P < 
0.001) of the EGF-induced Cl− current, and the inhibition was re-
versed upon return to 1T bathing solution containing EGF (n = 4, 
P = ns vs. initial EGF, 1T).Browe and Baumgarten 245
Figure 10. Proposed sim-
plifi   ed model of signaling 
coupling integrin stretch to 
activation of Cl− SAC. Integrin 
stretch activates FAK, Src, 
and other signaling pathways, 
which trigger the release of 
AngII from secretory vesicles. 
Binding of AngII and/or 
stretch initiate AT1 receptor 
signaling, which participates 
with FAK and Src in the trans-
activation of EGFR kinase 
and the subsequent down-
stream production of PI-3K. 
Components of these signal-
ing cascades, including PI-3K 
and Src, induce activation of 
p47phox, p67phox, and rac, which translocate to the membrane and assemble with gp91phox and p22phox to form the active NADPH oxidase 
complex. NADPH oxidase catalyzes the production of ⋅O2
−, which is rapidly converted to H2O2 by dismutation. H2O2 may activate Cl− 
SAC directly or via ROS-sensitive signaling pathways.
  under isosmotic conditions via the AngII signaling cas-
cade and involves AT1 receptors, Src/FAK signaling, and 
H2O2 generated, at least in part, by NADPH oxidase 
(Browe and Baumgarten, 2003, 2004). The present re-
sults indicate that EGFR kinase and PI-3K, which couple 
AT1 receptors to NADPH oxidase (Seshiah et al., 2002), 
are also components of the signaling cascade that evokes 
Cl− SAC in response to integrin stretch. Moreover, 
stretch- and EGF-induced currents were volume sensi-
tive, suggesting that they are carried by the same chan-
nels as ICl,swell.
A simple scheme accounting for both our present 
and previous fi  ndings is depicted in Fig. 10. Activation 
of Cl− SAC was abrogated by blockers of EGFR kinase, 
and exogenous EGF elicited a tamoxifen-sensitive cur-
rent that mimicked the Cl− SAC but turned on more 
rapidly. These data suggest that stretch stimulates Cl− 
SAC via EGFR kinase. PI-3K must be downstream from 
EGFR kinase because inhibition of PI-3K suppressed 
both the stretch- and EGF-induced current. PI-3K has 
been implicated in the translocation of Rac to the mem-
brane and the activation of NADPH oxidase (Seshiah 
et al., 2002; Vignais, 2002). Consistent with this idea, 
the EGF-induced Cl− current was blocked by gp91ds-
tat, a selective inhibitor of NADPH oxidase, and we 
previously demonstrated that stretch-induced Cl− cur-
rents are blocked by other NADPH oxidase inhibitors, 
diphenyleneiodonium (DPI) and AEBSF (Browe and 
Baumgarten, 2004). Two other signaling molecules in 
this cascade, AngII and H2O2, also elicit currents that 
mimic Cl− SAC in the absence of stretch, whereas the 
AT1 blocker losartan and degradation of H2O2 by cata-
lase inhibit Cl− SAC (Browe and Baumgarten, 2004). 
The idea that AT1 receptor activation leads to stimu-
lation of NADPH oxidase by a cascade that includes 
EGFR kinase and PI-3K is well established in other sys-
tems   (Seshiah et al., 2002). Although the simple linear 
scheme in Fig. 10 is suffi  cient to explain our observa-
tions on Cl− SAC, we cannot exclude additional interac-
tions between these signaling molecules.
Stretch- and osmotic swelling–induced Cl− currents 
share several biophysical and pharmacological character-
istics, and it has been suggested that Cl− SAC are carried 
by the same channels as ICl,swell (Browe and Baumgarten, 
2003, 2004). The present fi  ndings support this idea. Both 
the stretch- and EGF-induced currents were suppressed 
by osmotic shrinkage, and the EGF-induced current was 
blocked by tamoxifen, as previously shown for Cl− SAC 
(Browe and Baumgarten, 2003).
Cl− SAC and ICl,swell also are regulated by some of the 
same signaling pathways. Block of EGFR kinase inhibits 
the activation of ICl,swell by osmotic swelling in human 
atrial and rabbit ventricular myocytes (Du et al., 2004; 
Ren and Baumgarten, 2005), and recently we found 
that AT1 receptors, PI-3K, NADPH oxidase, and ROS 
play the same roles in eliciting ICl,swell upon osmotic 
swelling in rabbit ventricle (Ren et al., 2005) as in re-
sponse to integrin stretch. In contrast, block of Src fam-
ily protein tyrosine kinases with PP2 gives a result that 
depends on the stimulus. PP2 suppresses Cl− SAC 
(Browe and Baumgarten, 2003), whereas it stimulates 
ICl,swell after it has been activated by swelling (Du et al., 
2004; Ren and Baumgarten, 2005; Walsh and Zhang, 
2005). Walsh and Zhang (2005) also observed stimula-
tion of ICl,swell in neonatal rat myocytes when FAK was in-
hibited by overexpression of FRNK, an endogenous 
FAK inhibitor. On the other hand, Sorota (1995) 
found that nonselective tyrosine kinase inhibitors, 
which also should have inhibited Src and FAK, pre-
vented activation of ICl,swell in canine atrial myocytes; the 
reason for this discrepancy is unknown. It is also un-
clear why inhibition of Src and FAK stimulates ICl,swell 
in several preparations but inhibited Cl− SAC. Osmotic 
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family (Cohen, 2005), whereas PP2 broadly inhibits this 
protein tyrosine kinase family. Osmotic swelling also 
may give rise to signaling not elicited by stretch. Other 
signaling pathways are implicated in the regulation of 
ICl,swell (Hume et al., 2000; Baumgarten and Clemo, 
2003), but their role in regulation of Cl− SAC has not 
been tested.
Although we termed the stretch- and EGF-induced 
stimulation of Cl− current an activation, the present 
studies do not distinguish between de novo opening of 
channels that are silent in the absence of these stimuli 
and modulation of ICl,swell channels that are a major 
  contributor to the background outwardly rectifying Cl− 
current under isosmotic conditions (Hume et al., 2000). 
Block of EGFR kinase by AG1478 and PI-3K by LY 294002 
restored stretch- and EGF-induced current to their 
  control level but did not alter the background current in 
the absence of these stimuli. In contrast, the ICl,swell/Cl− 
SAC blocker tamoxifen and osmotic shrinkage inhibited 
both the stretch- and EGF-induced and the background 
current. These observations may suggest that back-
ground ICl,swell is regulated by signaling processes not 
studied here, but this requires further verifi  cation.
Regulation of Cl− SAC by EGFR Kinase Transactivation and EGF
The ErbB family of receptor tyrosine kinases is repre-
sented in mammals by EGFR kinase (ErbB1) and 
ErbB2–ErbB4, which form homo- and heterodimers 
(Bogdan and Klämbt, 2001; Holbro and Hynes, 2004). 
Two lines of evidence implicate EGFR kinase in Cl− 
SAC activation. First, 10 μM AG1478 completely 
blocked Cl− SAC during stretch, and intracellular pre-
treatment with a 10-fold lower concentration via the 
patch pipette suppressed Cl− SAC activation by subse-
quent stretch. AG1478 is a highly selective blocker that 
inhibits ATP binding to EGFR kinase with an IC50 of 
3 nM, whereas it is a weak inhibitor of ErbB2 and the 
platelet-derived growth factor receptor with an IC50 of 
>100 μM in both cases (Levitzki and Gazit, 1995). Sec-
ond, exogenous EGF activated an outwardly rectifying, 
tamoxifen-sensitive Cl− current that resembles Cl− SAC 
in the absence of stretch. EGF specifi   cally binds to 
EGFR kinase; ErbB3 and ErbB4 bind neuregulins, and 
no ligand is known for ErbB2 (Bogdan and Klämbt, 
2001; Holbro and Hynes, 2004). While these results 
clearly implicate EGFR kinase in Cl− SAC activation, we 
cannot rule out the possibility that other ErbB family 
members participate in signaling by forming heterodi-
mers with EGFR kinase.
This appears to be the fi  rst evidence that EGFR kinase 
mediates integrin signaling in cardiac myocytes. Several 
mechanisms for EGFR kinase transactivation have been 
identifi  ed. Integrins and EGFR colocalize and physically 
interact within macromolecular complexes at the cell 
membrane in human ECV304 cells and mouse fi  bro-
blasts, and integrin engagement transactivates EGFR 
  kinase in the absence of serum or exogenous growth 
factors (Moro et al., 2002; Cabodi et al., 2004). This de-
pends on the integrin cytoplasmic tail, the adaptor pro-
tein p130Cas, and Src, which phosphorylates EGFR 
kinase at tyr-845 and triggers autophosphorylation and 
downstream signaling. In addition, mechanical stretch 
and AT1 receptors transactivate EGFR kinase by a mech-
anism that depends on Src and H2O2 in a variety of cells 
(Ushio-Fukai et al., 2001; Oeckler et al., 2003; Kippen-
berger et al., 2005), and the carboxyl tail of AT1 recep-
tors directly interacts with and transactivates EGFR 
kinase after phosphorylation of AT1 Y319 (Seta and 
  Sadoshima, 2003). Thus, it is possible that integrin-
  mediated stretch directly activates EGFR kinase, or 
a factor directly linked to EGFR kinase activation, in a 
process that is independent of ligands for this receptor 
kinase. In this vein, it recently was reported that the 
AT1 receptor can be activated by stretch by a mecha-
nism independent of AngII binding (Zou et al., 2004).
An autocrine–paracrine mechanism for transactiva-
tion of EGFR kinase also is well established in the car-
diovascular system (Eguchi et al., 2003; Shah and Catt, 
2004). AT1 receptor activation stimulates Zn2+-depen-
dent matrix metalloproteinases (MMPs) that cleave 
membrane-tethered pro-heparin–binding EGF-like 
growth factor (proHB-EGF). This causes shedding of 
soluble heparin-binding EGF (HB-EGF), which is a li-
gand for EGF kinase. Moreover, integrins bind to and 
can activate MMP directly (Stanton et al., 1998) and co-
localize with proHB-EGF and EGFR kinase at the sur-
face membrane (Nakamura et al., 1995; Moro et al., 
2002; Cabodi et al., 2004). Shedding of HB-EGF may 
explain why the Cl− current elicited by stretch was about 
the same magnitude as that activated by exogenous EGF 
when only a small fraction of the integrins were stretched 
by magnetic beads. A large number of myocytes with at-
tached beads covered the chamber fl  oor and all were 
stretched simultaneously. Therefore, the cell under 
study was exposed to locally released HB-EGF and also 
to HB-EGF delivered by diffusion and solution fl  ow 
from other myocytes. Nevertheless, the relative impor-
tance of the various mechanisms for transactivation of 
EGFR kinase is unknown.
Identity of the EGF-induced Cl− Current
The primary Cl− currents traditionally recognized in 
cardiac myocytes include the PKA-dependent Cl− cur-
rent due to the cystic fi  brosis transmembrane conduc-
tance regulator (ICFTR,cardiac), the calcium-dependent 
transient outward Cl− current (ICl,Ca), and ICl,swell (Hume 
et al., 2000). The biophysical and pharmacological 
  profi  le and volume sensitivity of the EGF-induced Cl− 
  current are consistent with ICl,swell rather than either 
ICFTR,cardiac or ICl,Ca. The EGF-induced Cl− current and 
ICl,swell both activate over several minutes, outwardly 
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In contrast, ICFTR,cardiac is time independent at all volt-
ages under similar conditions (Hume et al., 2000). ICl,Ca 
is activated by cytoplasmic Ca2+ transients. With normal 
Ca2+   handling, ICl,Ca displays outward rectifi  cation and 
inactivates at positive potentials (Zygmunt and Gibbons, 
1991). If cytoplasmic Ca2+ is clamped at an elevated 
level, however, ICl,Ca is time independent. Under the 
present conditions, ICl,Ca should be negligible because 
the bathing solution was Ca2+ free, and Ca2+ transients 
were minimized by clamping the cytoplasmic free Ca2+ 
to   35 nM with 8 mM EGTA. In addition, the EGF-
  induced Cl− current was blocked by 10 μM tamoxifen 
as expected for ICl,swell (Vandenberg et al., 1994), but 
ICFTR,cardiac (Vandenberg et al., 1994) and ICl,Ca (Valverde 
et al., 1993) are insensitive to tamoxifen. Finally, both 
EGF-induced Cl− current and Cl− SAC were inhibited 
by myocyte shrinkage with 1.5T hyperosmotic bathing 
solution. Volume sensitivity is a fundamental character-
istic of ICl,swell that distinguishes it from ICFTR,cardiac and 
ICl,Ca (Hume et al., 2000). Thus the characteristics of the 
EGF-induced Cl− current resemble ICl,swell. We note, 
however, that the inward currents observed here are 
smaller than typical for ICl,swell. EGF elicits larger inward 
Cl− currents under different recoding conditions (un-
published data).
EGFR kinase previously was shown to modulate ICl,swell 
in human atrial (Du et al., 2004), rabbit ventricular (Ren 
and Baumgarten, 2005), and cultured neonatal rat ven-
tricular (Walsh and Zhang, 2005) myocytes under differ-
ent experimental conditions. Moreover, exogenous EGF 
potentiates ICl,swell in liver HTC (Varela et al., 2004) and 
mouse mammary C127 cells (Abdullaev et al., 2003), as 
well as hypotonicity-induced 125I− fl  ux in human intes-
tine 407 cells (Tilly et al., 1993). In the latter two studies, 
EGF did not activate anion current under isosmotic con-
ditions, however. EGF also up-regulated ICl,swell in LNCaP 
epithelial cells, but this was attributed to enhanced ex-
pression of ClC-3 (Lemonnier et al., 2004).
Regulation of Cl− SAC by PI-3K
Block of integrin stretch- and EGF-induced currents by 
wortmannin and LY 294002 argues for the participa-
tion of PI-3K in the response to both stimuli. Because 
inhibition of PI-3K suppressed the EGF-induced cur-
rent, these data also require that PI-3K is downstream 
from EGFR kinase in the signaling cascade (see 
Fig. 10), as documented by biochemical methods 
(  Bogdan and Klämbt, 2001). Osmotic activation of 
ICl,swell was shown to involve PI-3K in rabbit ventricular 
myocytes (Ren et al., 2005), smooth muscle (Wang 
et al., 2004), and epithelial cells (Shi et al., 2002) 
Moreover, mechanical stretch (Petroff et al., 2001), os-
motic swelling (Bewick et al., 1999), integrin activation 
(Franchini et al., 2000), AngII (Rabkin et al., 1997), 
and EGFR   kinase (Krieg et al., 2004) all stimulate 
PI-3K in cardiac myocytes.
Cardiac myocytes predominantly express class I PI-3K 
heterodimers; p110α-p85 is activated by RTK, and 
p110γ-p101 is activated by the βγ subunits of G proteins 
(Prasad et al., 2003; Oudit et al., 2004). Wortmannin 
covalently modifi  es the p110 catalytic subunit, whereas 
LY294002 is structurally distinct and competes with ATP 
for the p110 active site (Stein and Waterfi  eld, 2000; 
Oudit et al., 2004). The observation that 500 nM wort-
mannin suppressed only 67% of Cl− SAC may provide a 
clue as to which PI-3K isoform is involved. Wortmannin 
inhibits most PI-3K isoforms with an IC50 of 1–10 nM, 
but monomeric class II PI-3K-C2α, which also is ex-
pressed in heart, is relatively insensitive to wortmannin 
with an IC50 of  400 nM (Stein and Waterfi  eld, 2000; 
Oudit et al., 2004). The relative insensitivity of the PI-
3K-C2α isoform may explain why wortmannin only par-
tially inhibited Cl− SAC. Consistent with this idea, 
engagement of integrins activates PI-3K C2α in both 
platelets (Zhang et al., 1998) and smooth muscle cells 
(Paulhe et al., 2002). On the other hand, wortmannin, 
but not LY 294002, augmented the background current 
in the absence of stretch. The basis for this is unknown, 
but a stimulation of a background component of cur-
rent in the presence of stretch would appear as incom-
plete block of the stretch-induced current. It also must 
be recognized that neither wortmannin nor LY 294002 
is perfectly selective for PI-3K. Wortmannin inhibits my-
osin light chain kinase, and LY 294002 blocks casein ki-
nase-2, several K+ channels (Stein and Waterfi  eld, 2000; 
Oudit et al., 2004), and L-type Ca2+ channels (Welling 
et al., 2005). Because their nonspecifi  c actions differ, 
however, it seems likely that both antagonists are work-
ing here by suppressing the PI-3K pathway. Although 
there is no evidence to suggest that both wortmannin 
and LY 294002 block anion channels, we also cannot 
defi  nitively rule out this possibility.
Regulation of the EGF-induced Cl− Current by NADPH Oxidase
We previously demonstrated that integrin stretch and 
AngII elicit Cl− SAC in ventricular myocytes by activat-
ing NADPH oxidase and triggering the production of 
H2O2 (Browe and Baumgarten, 2004). The present re-
sults indicate that the EGF-induced current also de-
pends on NADPH oxidase. A membrane-permeant 
fusion peptide inhibitor of NADPH oxidase assembly, 
gp91ds-tat, that mimics the docking site on gp91phox for 
p47phox (Rey et al., 2001) completely blocked Cl− SAC 
activation by EGF. In contrast, neither the inactive mem-
brane-permeant fusion peptide scramb-tat nor the ac-
tive but impermeant gp91ds docking sequence 9-mer 
altered the EGF-induced current. These results are con-
sistent with the expected intracellular site of action of 
the docking sequence and rule out nonspecifi  c effects 
of the tat 9-mer and block of Cl− channels by gp91ds 
from the outside. Two recent reports also conclude that 
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NADPH oxidase in HeLa and liver HTC cells based on 
block of current by DPI (Shimizu et al., 2004; Varela 
et al., 2004) and expression of the dominant negative 
p47phox mutant p47S379A (Varela et al., 2004).
An advantage of gp91ds-tat relative to more commonly 
used NADPH oxidase inhibitors is its specifi  city, which 
arises from peptide–peptide interactions. This peptide 
does not affect the activity of other fl  avocytochrome en-
zymes or act as an O2
− scavenger (Rey et al., 2001). In 
contrast, DPI, one of the most widely used inhibitors of 
NADPH oxidase activity, blocks other fl  avin-containing 
enzymes, including xanthine oxidase (Dous    siere and 
  Vignais, 1992), mitochondrial complex I (Majander et al., 
1994), and nitric oxide synthase (Stuehr et al., 1991). 
Although gp91ds-tat is specifi  c for NADPH oxidase, it 
apparently does not distinguish between isoforms 
  because the docking sites for p47phox are homologous 
(Rey et al., 2001). Cardiac myocytes express both the 
phagocyte-like gp91phox (Nox2) isoform (Li et al., 2002; 
Xiao et al., 2002; Heymes et al., 2003) and the Nox4 
  homologue (Byrne et al., 2003). We also cannot rule 
out the possibility that other sources of ROS are acti-
vated by stretch or EGF and participate in the regula-
tion of Cl− SAC. In preliminary experiments, we found 
that acetylcholine elicits a tamoxifen-sensitive Cl− 
  current that is blocked by 5-hydroxydecanoate, impli-
cating mitochondrial KATP channels or succinate de-
hydrogenase (Browe and Baumgarten, 2005a), and by 
rotenone, an inhibitor of mitochondrial complex I (un-
published data).
EGFR kinase and PI-3K participate in the activation of 
NADPH oxidase and the generation of ROS in response 
to diverse stimuli in several tissues. Examples include 
AngII- and prostaglandin F2α receptor–induced hyper-
trophy of vascular smooth muscle cells (Seshiah et al., 
2002; Fan et al., 2005), pressure-induced ROS produc-
tion in mouse aortic rings (Jung et al., 2004), and exog-
enous EGF-induced ROS production in Caco-2 and 
HEK293T cells (Park et al., 2004). Other growth fac-
tors, such as PDGF (Marumo et al., 1997) and insulin 
(Ceolotto et al., 2004), also stimulate NADPH oxidase 
in nonphagocytic cells by PI-3K signaling. Furthermore, 
β2 integrin and CD40 engagement elicit NADPH oxi-
dase in leukocytes by a process that requires PI-3K activ-
ity (Yamamori et al., 2000; Ha and Lee, 2004).
PI-3K regulates NADPH oxidase assembly and activa-
tion by several mechanisms. First, PI-3K leads to phos-
phorylation of the p47phox subunit, possibly by stimulation 
of Akt/PKB (Hoyal et al., 2003) or PKC (Yamamori 
et al., 2000). Second, PtdIns(3,4,5)P3 and PtdIns(3,4)P2, 
the products of PI-3K, bind to PX domains in p47phox 
and p40phox (Kanai et al., 2001; Zhan et al., 2002), direct-
ing these subunits to the plasma membrane. Third, PI-
3K stimulates Rac, which also is required for NADPH 
oxidase assembly (Vignais, 2002). PtdIns(3,4,5)P3 and 
PtdIns(3,4)P2 bind and activate guanine nucleotide 
  exchange factors for Rac and, thereby, trigger Rac acti-
vation via GDP–GTP exchange (Park et al., 2004). 
  Finally, H2O2 generated by NADPH oxidase feeds for-
ward to potentiate RTK-PI-3K signaling by inhibiting 
protein   tyrosine phosphatases (Knebel et al., 1996; Bae 
et al., 1997) and the lipid phosphatase PTEN (Rhee 
et al., 2003), which dephosphorylate the targets of RTK 
and PI-3K, respectively. H2O2 also feeds forward by trig-
gering HB-EGF– (Frank and Eguchi, 2003) and Src-
  induced (Chen et al., 2001; Sato et al., 2003) EGFR 
kinase phosphorylation. These actions of H2O2 may in 
part explain its activation of Cl− SAC in the absence of 
stretch (Browe and Baumgarten, 2004).
Cl− SAC Regulation and Cardiac Pathophysiology
HB-EGF, EGFR kinase, PI-3K, NADPH oxidase, and 
ICl,swell are concurrently up-regulated in chronic cardiac 
disease. Exogenous EGF induces hypertrophic responses 
in ventricular myocytes (Rebsamen et al., 2000). HB-
EGF is up-regulated in the peri-infarct region after myo-
cardial infarction (Iwabu et al., 2002), and enhanced 
expression and activation of HB-EGF and EGFR kinase 
are key elements of pressure overload– and G protein 
coupled receptor–induced cardiac hypertrophy (Shah 
and Catt, 2004; Smith et al., 2004). The Gβγ-  regulated 
p110γisoform of PI-3K is implicated in maladaptive 
cardiac hypertrophy triggered by both pressure over-
load and G protein–coupled receptors, and knockout 
of p110γ prevents heart failure induced by β-adren-
ergic agonists (Prasad et al., 2003; Oudit et al., 2004). 
A DPI-sensitive increase in ⋅O2
− production by myocytes 
accompanies the development of cardiac hypertrophy 
and heart failure and is due to increased expression 
and/or membrane translocation of NADPH oxidase 
subunits (Li et al., 2002; Heymes et al., 2003). Consis-
tent with the concurrent up-regulation of its regulatory 
factors, cardiac Cl− current identifi  ed as ICl,swell is persis-
tently active under isosmotic conditions in cardiac my-
ocytes isolated from rat, rabbit, and canine models of 
hypertrophy and heart failure and from the peri-infarct 
zone 30 d after myocardial infarction (Bénitah et al., 
1997; Clemo et al., 1999; Baumgarten and Clemo, 2003; 
c.f., van Borren et al., 2002). Nevertheless, other signal-
ing molecules also may be involved in the regulation of 
ICl,swell in cardiac disease.
Limitations
Two limitations of this study should be noted. First, 
signaling pathways were identifi   ed with various ag-
onists and antagonists. Although these agents have 
been well characterized in the literature, the possibil-
ity that nonspecifi  c effects confound our interpreta-
tion should be considered. Second, experiments were 
conducted at a subphysiologic temperature. This may 
have had a quantitative or even a qualitative impact on 
the observations.Browe and Baumgarten 249
In summary, β1 integrin stretch elicited Cl− SAC in 
ventricular myocytes by transactivation of EGFR kinase 
and downstream stimulation of PI-3K and NADPH 
  oxidase. Exogenous EGF activated tamoxifen-sensitive 
Cl− SAC in the absence of stretch by a process that also 
involved PI-3K and NADPH oxidase. Furthermore,   
Cl− SAC was volume sensitive and was suppressed by os-
motic shrinkage in the presence of stretch or EGF. Thus, 
it is likely that the Cl− SAC is mediated by the same 
channel as ICl,swell.
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